Characterization of Autoreactive B Cells in Autoimmune Diseases and Immune Deficiencies
Official title: Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies
Run by University Hospital, Strasbourg, France · NCT07251179 · Data updated 2026-11-12
Researchers are testing to see how autoreactive B cells behave in people with autoimmune diseases or immune deficiencies to better understand how these cells may contribute to disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Drugs / interventions | CAR T, chimeric antigen receptor |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | January 20, 2026 |
| Main results expected | December 31, 2031 |
| Study ends | December 31, 2031 |
| Registry record updated | August 20, 2026 |
| Trial ID | NCT07251179 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–70 with one of the specified autoimmune or immunodeficiency conditions and able to consent to genetic testing.
✕Probably not a fit
Patients without autoreactive B-cell dysregulation similar to those studied may see no direct benefit from this observational analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study analyzes autoreactive B lymphocytes in adults with systemic lupus erythematosus, systemic scleroderma, ANCA-associated vasculitis, antiphospholipid syndrome, or primary immunodeficiencies. Blood samples are collected to characterize B-cell populations and their tolerance checkpoints. The study aims to identify patterns that could explain why B-cell–targeted therapies have variable success. Results may inform future strategies for more precise patient matching and therapy selection. The research is conducted at Hôpitaux Universitaires de Strasbourg under the lead sponsor University Hospital, Strasbourg.
Why it matters
Potential benefit: Findings could improve understanding of which patients might benefit from B-cell–targeted therapies and guide more personalized treatment approaches.
How similar studies have gone: Similar approaches have yielded insights into B-cell biology in autoimmune diseases, supporting the value of this characterization, though individual utility may vary.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged between 18 and 70 * Patients for whom at least one of the following conditions has been confirmed: * Systemic lupus erythematosus meeting the 2019 ACR/EULAR classification criteria. * Systemic scleroderma meeting the 2013 ACR/EULAR classification criteria. ANCA-associated vasculitis according to the 2022 EULAR/ACR classification criteria. * Antiphospholipid syndrome according to the 2023 ACR/EULAR criteria. * Primary immunodeficiencies according to IUIS criteria. * Patients capable of understanding the objectives of the research. * Patients affiliated with a social security health insurance scheme (beneficiary or dependant). * Patients who have signed and dated the informed consent form for non-identifying genetic testing. Exclusion Criteria: * Patient refusing to participate in the study * Patient in a period of exclusion (determined by a previous or ongoing study) Inability to provide the subject with informed consent (in an emergency or immediate life-threatening situation, difficulties in understanding the subject, etc.) * Patient under legal protection * Patient under guardianship or conservatorship
Where it's running
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Anne-Sophie KORGANOW, MD
- Email: anne-sophie.korganow@chru-strasbourg.fr
- Phone: 03 69 55 09 94
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BCMA-CD19 CAR-T therapy for autoimmune diseases
This study is testing a new CAR-T cell therapy to see if it can help adults with tough autoimmune diseases feel better and improve their health.
-
CR-402 treatment for refractory autoimmune disease
This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.
-
BCT301 CAR-iT cell therapy for hard-to-treat autoimmune diseases
This early‑phase study tests whether off-the-shelf BCT301 CAR-iT cells can be given safely to adults with refractory autoimmune diseases to see if they can be tolerated and what dose works best.
-
YTS109 cell therapy for relapsed or refractory autoimmune diseases
This will try a single infusion of YTS109 immune cells to see if they are safe and help adults 18–65 with relapsed or refractory lupus (including lupus nephritis), Sjogren's syndrome, inflammatory myopathy, or ANCA‑associated vasculitis.
-
Imaging in Inflammatory Heart Diseases linked to autoimmune disorders
This study tests how well multimodality imaging (CMR, echocardiography, and PET) detects inflammation in people with suspected inflammatory heart or autoimmune rheumatic diseases.
-
Using engineered immune cells to treat difficult autoimmune diseases
This study is testing if a new type of immune cell treatment can help people with tough autoimmune diseases that haven't responded to other therapies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.